The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses.
Gaggar describe
Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and d...
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to...
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year...
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
